Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

DeVita, 2004 Rosenberg, 1994, Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2, JAMA, 271, 907, 10.1001/jama.1994.03510360033032 Rosenberg, 1998, Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigen-mediating response, Ann Surg, 228, 307, 10.1097/00000658-199809000-00004 Fisher, 2000, Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma, Cancer J Sci Am, 6, S55 Thompson, 2003, A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma, Clin Cancer Res, 9, 3562 Visonneau, 2000, Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer, Clin Cancer Res, 6, 1744 Miller, 2001, The biology of natural killer cells in cancer, infection, and pregnancy, Exp Hematol, 29, 1157, 10.1016/S0301-472X(01)00696-8 Tonn, 2001, Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92, J Hematother Stem Cell Res, 10, 535, 10.1089/15258160152509145 Tam, 2003, Ex vivo expansion of the highly cytotoxic human natural killer cell line NK-92 under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy, Cytotherapy, 5, 259, 10.1080/14653240310001523 Yan, 1998, Antileukemia activity of a natural killer cell line against human leukemias, Clin Cancer Res, 4, 2859 Tam, 1999, Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92, J Hematother, 8, 281, 10.1089/106161299320316 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumours: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Rosenberg, 1985, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N Eng J Med, 313, 1485, 10.1056/NEJM198512053132327 Benyunes, 1993, Interleukin-2 with or without lymphokine-activated killer cell as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia, Bone Marrow Transplant, 12, 159 Rosenberg, 1993, Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer, J Natl Cancer Inst, 85, 622, 10.1093/jnci/85.8.622 Velardi, 2002, NK cells: a lesson from mismatched hematopoietic transplantation, Trends Immunol, 23, 438, 10.1016/S1471-4906(02)02284-6 Passweg, 2004, Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation, Leukemia, 18, 1835, 10.1038/sj.leu.2403524 Miller, 2005, Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, 105, 3051, 10.1182/blood-2004-07-2974 Hoff, 1998, The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia, Cancer, 82, 1585, 10.1002/(SICI)1097-0142(19980415)82:8<1585::AID-CNCR22>3.0.CO;2-# Berman, 2001, Hypoglycemia caused by secretion of insulin-like growth factor 2 in a primary renal cell carcinoma, Clin Oncol (R Coll Radiol), 13, 367 Silverman, 1989, Metabolic emergencies in clinical oncology, Semin Oncol, 16, 504 Moretta, 2005, Human natural killer cells: molecular mechanisms controlling NK cell activation and tumor cell lysis, Immunol Lett, 100, 7, 10.1016/j.imlet.2005.07.004 Ruggeri, 2002, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, 295, 2097, 10.1126/science.1068440 Uherek, 2002, Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction, Blood, 100, 1265, 10.1182/blood.V100.4.1265.h81602001265_1265_1273 Mueller T, Uherek C, Maki G et al. Expression of a CD20-specific antigen receptor enhances activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother, in press.